Multicenter study on the safety of bariatric endoscopy

Coll, Eduardo Espinet; Durán, Javier Nebreda; Breviere, Gontrand López-Nava; J, Garcia; Rodríguez-Téllez, Manuel; Crespo, Javier; Valenciano, Carlos Marra-López

doi:10.17235/reed.2017.4499/2016

Cited by 14 publications

(6 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Even if Espinet-Coll et al (13) described the risk of suture passing close to the hilum of the spleen with the risk of catastrophic hemorrhage and the need for splenectomy in our experience no major adverse events occurred during the procedure. In another study, Lopez-Nava et al (14) assessed 248 patients treated with EG using the Apollo OverStitch system (2017).…”

Section: Discussionmentioning

confidence: 45%

Endoscopic Gastroplasty. Initial Experience

Manos¹,

Noe͏̈l²,

Bastid³

et al. 2019

chr

View full text Add to dashboard Cite

RezumatIntroducere: Procedurile bariatice endoscopice, în curs de dezvoltare, sunt mult mai puţin invazive ca opţiune de tratament pentru clasa I de obezitate. Scopul studiului nostru a fost de a evalua experienţa iniţială pe un an cu gastroplastia endoscopică (GE) din punct de vedere al rezultatelor ponderale, cât şi pentru evaluarea riscurilor acestei noi proceduri. Metode: Acesta este un studiu prospectiv într-un singur centru pe 17 pacienţi care au beneficiat de GE sub anestezie generală. Variabilele analizate au fost: modificarea greutăţii corporale şi complicaţiile procedurii. Pentru a analiza corelaţiile dintre IMC şi pentru a identifica factorii predictori pentru o mai bună pierdere în greutate după GE, pacienţii au fost divizaţi în 2 grupuri: grupa A (cu IMC < 35 şi fără antecedente bariatrice -10 pacienţi) şi grupa B (cu IMC > 35, sau cu antecedente de balon gastric sau chirurgie bariatrică -7 cazuri). Rezultate: Un total de 17 pacienţi au beneficiat de GE pentru obezitatea primară sau recidivă. Toţi pacienţii au fost de sex feminin, cu o vârstă medie de 38,7 ani. Media IMC a fost de 34,8 kg /m 2 (interval: 30,8 -44,1). Nu au existat complicaţii în timpul procedurii sau în perioada de după. Toţi pacienţii au fost externaţi în prima sau a doua zi după procedură, iar în viitor procedura va fi propusă în ambulatoriu. Patru pacienţi (23,5%) au prezentat durere postprocedurală moderată pe o perioadă medie de 7,75 zile (interval de 2-15 zile), iar alţi doi pacienţi au prezentat greaţă şi

show abstract

Section: Discussionmentioning

confidence: 45%

Endoscopic Gastroplasty. Initial Experience

Manos¹,

Noe͏̈l²,

Bastid³

et al. 2019

chr

View full text Add to dashboard Cite

show abstract

“…At this level the previous mentioned filling catheter is adjusted and, by aspiration of 100 to 300 mL, the balloon volume is appropriately reduced. The same process is followed, usually 3 mo after implantation when the patient stops or has minimized weight loss, or should he/she report a decrease in satiety, to increase the balloon volume by a standard volume of 250 mL[ 43 , 46 ]. At the end the 12-mo implantation period, the balloon must be removed endoscopically after emptying by standard balloon needle or deflation utilizing the valve, by the same process as for insertion.…”

Section: Balloon Descriptionmentioning

confidence: 99%

“…After a 4 mo period, the device is designed to spontaneously empty; the reabsorbable material, remaining closed inside the sealing balloon valve, completely degrades, leaving the device to self - deflate and then naturally pass - thanks to its construction from a thin film without rigid parts-through the gastrointestinal tract and be excreted[ 35 , 36 , 46 , 57 , 58 ].…”

Section: Balloon Descriptionmentioning

confidence: 99%

Six intragastric balloons: Which to choose?

Stavrou¹,

Shrewsbury²,

Kotzampassi³

2021

WJGE

View full text Add to dashboard Cite

Endoscopically placed intragastric balloons (IGBs) have played a significant role in obesity treatment over the last 30 years, successfully bridging the gap between lifestyle modification/pharmacotherapy and bariatric surgery. Since they provide a continuous sensation of satiety that helps the ingestion of smaller portions of food, facilitating maintenance of a low-calorie diet, they have generally been considered an effective and reversible, less invasive, non-surgical procedure for weight loss. However, some studies indicate that balloons have limited sustainable effectiveness for the vast majority attempting such therapy, resulting in a return to the previous weight after balloon removal. In this review we try to summarize the pros and cons of various balloon types, to guide decision making for both the physician and the obese individual looking for effective treatment. We analyzed the six most commonly used IGBs, namely the liquid-filled balloons Orbera, Spatz3, ReShape Duo and Elipse, and the gas-filled Heliosphere and Obalon - also including comments on the adjustable Spatz3, and the swallowable Obalon and Elipse - to optimize the choice for maximum efficacy and safety.

show abstract

“…Since that time, the procedure and suturing pattern has continued to evolve (Figure 6). The procedure has been studied extensively with TBWL of 14.4% to 15.2% at 6 months, 17.6% at 12 months, and 18.6% to 20.9% at 24 months 34–39 . In addition to being more durable at weight loss, few adverse events have been reported.…”

Section: Fda Approved Endoscopic Therapiesmentioning

confidence: 99%

The current state of bariatric endoscopy

McCarty

Thompson

2020

Digestive Endoscopy

View full text Add to dashboard Cite

A variety of endoscopic bariatric and metabolic treatments (EBMTs) have been developed in recent years to combat the growing prevalence of obesity in the United States (US) and worldwide. This manuscript reviews the current state of bariatric endoscopy, detailing all US Food and Drug Administration (FDA) approved EBMTs including space‐occupying intragastric balloons (IGBs), aspiration therapy, and endoscopic tissue apposition devices. Additionally, this review describes non‐FDA approved treatments including additional IGBs, endoluminal bypass liners, duodenal mucosal resurfacing, and endoscopically placed anastomosis devices.

show abstract

Multicenter study on the safety of bariatric endoscopy

Cited by 14 publications

References 32 publications

Endoscopic Gastroplasty. Initial Experience

Endoscopic Gastroplasty. Initial Experience

Six intragastric balloons: Which to choose?

The current state of bariatric endoscopy

Contact Info

Product

Resources

About